U.S. President Donald Trump , Eli Lilly and Novo Nordisk unveiled a deal on Thursday to slash the prices of popular GLP-1 weight‑loss drugs like Ozempic for the government’s Medicare and Medicaid programs, as well as for cash payers.

The move is aimed at increasing access to the treatments through U.S. Medicare for people aged 65 and over and the Medicaid program for low-income people, which together provide healthcare coverage for nearly half of all Americans.

U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations, and Trump has been pressuring drugmakers to lower their prices to what patients pay elsewhere.

“GLP-1s have been top of mind and not just because of the cardiometabolic benefits that they

See Full Page